Your browser doesn't support javascript.
loading
Opportunities and potential challenges of using terbium-161 for targeted radionuclide therapy in clinics.
Müller, Cristina; van der Meulen, Nicholas P; Schibli, Roger.
Affiliation
  • Müller C; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Forschungsstrasse 111, Villigen-PSI, Switzerland. cristina.mueller@psi.ch.
  • van der Meulen NP; Department of Chemistry and Applied Biosciences, ETH Zurich, Vladimir-Prelog-Weg 1-5/10, Zurich, Switzerland. cristina.mueller@psi.ch.
  • Schibli R; Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Forschungsstrasse 111, Villigen-PSI, Switzerland.
Eur J Nucl Med Mol Imaging ; 50(11): 3181-3184, 2023 09.
Article in En | MEDLINE | ID: mdl-37436459
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Radioisotopes / Terbium Limits: Humans Language: En Journal: Eur J Nucl Med Mol Imaging Journal subject: MEDICINA NUCLEAR Year: 2023 Document type: Article Affiliation country: Switzerland Country of publication: Germany
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Radioisotopes / Terbium Limits: Humans Language: En Journal: Eur J Nucl Med Mol Imaging Journal subject: MEDICINA NUCLEAR Year: 2023 Document type: Article Affiliation country: Switzerland Country of publication: Germany